Studio E.R. Congressi
Monday, November 4, 2019
Session I: Genomic Landscapes
Chairmen: G. Gaidano, D. Rossi
CLL pathogenesis: microenviromental and genetics
The role of microRNA in CLL pathogenesis
Session II: Chemoimmunotherapy
Chairmen: M. Hallek, C. Tam
Chlorambucil plus anti-CD20
Comorbidities and other cancers
Session III: Novel Targeted Therapies
Chairmen: P. Ghia, S.M. O’Brien
Second generation BTK Inhibitor
Management of side-effects during targeted therapy
Drivers of treatment patterns in patients stopping ibrutinib or idelalisib
Session IV: Richter Syndrome
Chairman: A. Cuneo
Is there a potential risk of an increased rate of Richter Syndrome with the advent of targeted therapy?
Treatment approach in the era of novel therapies
Session V: Further Innovative Therapeutical Approaches
Chairman: S.M. O’Brien
When and how to use allotransplant
Tuesday, November 5, 2019
Session VI: Newer Agents
Chairmen: A.R. Mato, P.L. Zinzani
Next-generation BTK inhibitors: Zanubrutinib
Next-generation BTK inhibitors: ARQ531
Other PI3K inhibitors: Duvelisib
Other PI3K inhibitors: Umbralisib
SESSION VII: Interesting Observations/Questions
Chairmen: J.A. Burger, R. Foà
The stop of the treatment with the new targeted therapies: will it be possible in the future?
Which are the best combinations of therapies using targeted agents?
How should we sequence these novel agents?
Studio E.R. Congressi s.r.l.
Via de' Poeti, 1
40124 Bologna BO